MUSILOVÁ, Romana, Eva TÁBORSKÁ, H. NOVOTNÁ, Ludmila BOURKOVÁ, L. KOVÁŘOVÁ, Tomáš BÜCHLER, Miroslav PENKA and Roman HÁJEK. Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography. In Zborník XVII.Biochemický zjazd. Bratislava, SR: VEDA, vydavatelstvo SAV, Bratislava, 2002, p. 223. ISBN nepřiděleno.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography
Authors MUSILOVÁ, Romana (203 Czech Republic), Eva TÁBORSKÁ (203 Czech Republic), H. NOVOTNÁ (203 Czech Republic), Ludmila BOURKOVÁ (203 Czech Republic), L. KOVÁŘOVÁ (203 Czech Republic), Tomáš BÜCHLER (203 Czech Republic), Miroslav PENKA (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor).
Edition Bratislava, SR, Zborník XVII.Biochemický zjazd, p. 223-223, 2002.
Publisher VEDA, vydavatelstvo SAV, Bratislava
Other information
Original language English
Type of outcome Proceedings paper
Field of Study 30200 3.2 Clinical medicine
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/02:00006850
Organization unit Faculty of Medicine
ISBN nepřiděleno
Keywords in English multiple myeloma; IgG; affinity chromatography; G-protein
Tags affinity chromatography, G-protein, IgG, multiple myeloma
Changed by Changed by: prof. RNDr. Eva Táborská, CSc., učo 1068. Changed: 9/12/2002 10:30.
Abstract
Multiple myeloma is characterized by the proliferation of a malignant plasma cell clone and accounts for approximately 10% of hematological malignancies. High-dose chemotherapy with autologous transplantation has improved the survival of patients with myeloma, hovewer, relapse is inevitable (1,2). Recent research has targeted the minimal residual disease. One of the therapeutical options is this setting is immunotherapy using specific tumor antigen as a vaccine. The idiotype of myeloma immunoglobulin (Id protein) is specifically expressed by malignant cells and can be used as a tumor antigen with the aim to induce cytotoxic T-lymphocyte response against myeloma cells (3,4,5,6). For purification of Id protein from plasma of relapsed IgG myeloma patients who were before reinduction treatment, plasma was precipitated with a saturated solution of ammonium sulfate. After precipitation and dialysis in saline at pH 7.3 to remove ammonium sulfate, the Id protein was separated on protein G immobilized on agarose. To breach the bound between the Id-protein and the protein G, 0.2M glycine (pH 2.7) was used and resulting fractions were immediately neutralized in 1M Tris-base. SDS-polyacrylamide gel electrophoresis was used to determine the purity of Id protein. The isolation was carried out in 10 patients. Using columns with a capacity of 30 mg/ml protein G and the flow rate of 1-2 drops per 10 seconds, 47% of the plasma content of Id protein was extracted (range: 22 to 89%). The initial concentration of monoclonal immunoglobulin in plasma did not influence the yield of the separation. The amount of Id protein extracted in each isolation was sufficient to a prepare Id-KLH conjugate that was used as the specific antigen in preclinical experiments.
Links
NC6763, research and development projectName: Využití monoklonálního imunoglobulinu k přípravě protinádorové vakcíny u nemocných s mnohočetným myelomem
Investor: Ministry of Health of the CR, Use of monoclonal immunoglobulin for preparation of antitumor vaccine in patients with multiple myeloma
PrintDisplayed: 24/7/2024 12:30